Browse drugs

… followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment seque…

…or triptans, respectively, reported treatment optimization. For rimegepant, 95% of physicians and 97% of patients reported satisfaction wi…

…mastobart, and no treatment-related deaths occurred.Conclusions Nelmastobart combined with capecitabine demonstrated a manageable safety pro…

…gimen start.Results Of 46 evaluable patients, 24 (52%) received ICI monotherapy and 22 (48%) received ICI-based combinations. Six p…

…ells, both in vitro and in vivo. These results findings support SynKIR-110 as a promising candidate with improved safety and efficacy for …

…cyte count (ALC) identifies a subgroup unlikely to benefit from pembrolizumab.Methods We performed a single-center retrospective study of adu…

…ALB2) in altering inflammatory signals in response to PARPi and ICi. This data may guide the clinical development of such combinati…

…W, Schlom J, Gulley J. 616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Re…

…linded), vibo/pembro alone (arm 2; open label), or placebo plus docetaxel (arm 3; blinded). PD-L1 expression was assessed using PD-L1 IHC…

…g Ki-67, PD-1, CD25, HLA-DR, CD137, TIM-3 and LAG-3.Conclusions ISB 2001 demonstrated dose proportional PK, a high ORR and acceptable sa…

…ective of Phase 1 is to evaluate the safety and tolerability of KSQ-004EX. In Phase 2, patients will be enrolled in indication-specific c…

…ill be enrolled in the dose-escalation cohorts and administered STC-15 orally thrice weekly (TIW) at 3 escalating dose levels in combi…